Sinopsis
PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
Episodios
-
![Managing Perianal Fistulas in Crohnrsquos Disease: Can We Do More?]()
Managing Perianal Fistulas in Crohn’s Disease: Can We Do More?
14/08/2019 Duración: 31minManaging Perianal Fistulas in Crohn’s Disease: Can We Do More?
-
![Maximising the Long-Term Treatment Plan for Unresectable Hepatocellular Carcinoma: A Sequential Approach to Improving Patient Outcomes]()
Maximising the Long-Term Treatment Plan for Unresectable Hepatocellular Carcinoma: A Sequential Approach to Improving Patient Outcomes
08/07/2019 Duración: 20minMaximising the Long-Term Treatment Plan for Unresectable Hepatocellular Carcinoma: A Sequential Approach to Improving Patient Outcomes
-
![The Power of Personalised Medicine: CAR-T Immunotherapy for Treatment of Aggressive Large B-Cell Lymphoma]()
The Power of Personalised Medicine: CAR-T Immunotherapy for Treatment of Aggressive Large B-Cell Lymphoma
05/07/2019 Duración: 21minThe Power of Personalised Medicine: CAR-T Immunotherapy for Treatment of Aggressive Large B-Cell Lymphoma
-
![Acute Kidney Injury After Cardiac Surgery: Optimising Outcomes in High-Risk Patients]()
Acute Kidney Injury After Cardiac Surgery: Optimising Outcomes in High-Risk Patients
19/06/2019 Duración: 17minAcute Kidney Injury After Cardiac Surgery: Optimising Outcomes in High-Risk Patients
-
![Meeting the Clinical Challenge: Individualising Anticoagulation for Patients With AF and ACS]()
Meeting the Clinical Challenge: Individualising Anticoagulation for Patients With AF and ACS
14/06/2019 Duración: 23minMeeting the Clinical Challenge: Individualising Anticoagulation for Patients With AF and ACS
-
![Optimising the Treatment of mRCC From the Start: Evaluating the Impact of Evolving First-Line Strategies]()
Optimising the Treatment of mRCC From the Start: Evaluating the Impact of Evolving First-Line Strategies
10/06/2019 Duración: 16minOptimising the Treatment of mRCC From the Start: Evaluating the Impact of Evolving First-Line Strategies
-
![Teaming Up to Improve Outcomes in Immunology: The Importance of an Integrated Approach to Disease Control]()
Teaming Up to Improve Outcomes in Immunology: The Importance of an Integrated Approach to Disease Control
03/06/2019 Duración: 19minTeaming Up to Improve Outcomes in Immunology: The Importance of an Integrated Approach to Disease Control
-
![Elimination of Hepatitis C: Simple Changes for Comprehensive Results]()
Elimination of Hepatitis C: Simple Changes for Comprehensive Results
31/05/2019 Duración: 20minElimination of Hepatitis C: Simple Changes for Comprehensive Results
-
![Beyond Positive and Negative HER2 Status: Defining HER2 Levels in Breast Cancer]()
Beyond Positive and Negative HER2 Status: Defining HER2 Levels in Breast Cancer
27/05/2019 Duración: 19minBeyond Positive and Negative HER2 Status: Defining HER2 Levels in Breast Cancer
-
![Targeting Remission in Auto-Inflammatory Diseases With Anti─IL-1β]()
Targeting Remission in Auto-Inflammatory Diseases With Anti─IL-1β
24/05/2019 Duración: 45minTargeting Remission in Auto-Inflammatory Diseases With Anti─IL-1β
-
![Imagining a World Without Hepatitis C Virus: A Call to Action]()
Imagining a World Without Hepatitis C Virus: A Call to Action
22/05/2019 Duración: 10minImagining a World Without Hepatitis C Virus: A Call to Action
-
![Aiming Higher in Advanced Cutaneous Squamous Cell Carcinoma: Experts Evaluate the Evidence for Immunotherapy]()
Aiming Higher in Advanced Cutaneous Squamous Cell Carcinoma: Experts Evaluate the Evidence for Immunotherapy
17/05/2019 Duración: 28minAiming Higher in Advanced Cutaneous Squamous Cell Carcinoma: Experts Evaluate the Evidence for Immunotherapy
-
![Emerging ‘Tumour-Agnostic’ Oncology Treatment: The Role of the Pathologist in Identifying Neurotrophic Tyrosine Kinase Gene Fusions]()
Emerging ‘Tumour-Agnostic’ Oncology Treatment: The Role of the Pathologist in Identifying Neurotrophic Tyrosine Kinase Gene Fusions
03/05/2019 Duración: 25minEmerging ‘Tumour-Agnostic’ Oncology Treatment: The Role of the Pathologist in Identifying Neurotrophic Tyrosine Kinase Gene Fusions
-
![Merging Clinical Trial Results and Reality: The Real-World Implications of Androgen Receptor Antagonists for Non–Metastatic Castration-Resistant Prostate Cancer]()
Merging Clinical Trial Results and Reality: The Real-World Implications of Androgen Receptor Antagonists for Non–Metastatic Castration-Resistant Prostate Cancer
29/04/2019 Duración: 29minMerging Clinical Trial Results and Reality: The Real-World Implications of Androgen Receptor Antagonists for Non–Metastatic Castration-Resistant Prostate Cancer
-
![A Case for Clarity: Putting the Latest Recommendations for IPF Into Context]()
A Case for Clarity: Putting the Latest Recommendations for IPF Into Context
22/04/2019 Duración: 10minA Case for Clarity: Putting the Latest Recommendations for IPF Into Context
-
![Should We Be Treating Ulcerative Colitis as a Progressive Disease?]()
Should We Be Treating Ulcerative Colitis as a Progressive Disease?
29/03/2019 Duración: 15minShould We Be Treating Ulcerative Colitis as a Progressive Disease?
-
![Learning From the Literature: The Latest Evidence on JAK Inhibitors for RA]()
Learning From the Literature: The Latest Evidence on JAK Inhibitors for RA
20/03/2019 Duración: 16minLearning From the Literature: The Latest Evidence on JAK Inhibitors for RA
-
![Optimising Outcomes for Young Women With Breast Cancer: The Role of Adjuvant Ovarian Suppression]()
Optimising Outcomes for Young Women With Breast Cancer: The Role of Adjuvant Ovarian Suppression
15/03/2019 Duración: 21minOptimising Outcomes for Young Women With Breast Cancer: The Role of Adjuvant Ovarian Suppression
-
![A Closer Look at Safety of Glucose-Lowering Therapy]()
A Closer Look at Safety of Glucose-Lowering Therapy
27/02/2019 Duración: 18minA Closer Look at Safety of Glucose-Lowering Therapy
-
![Managing Patients With HER2-Low Breast Cancer]()
Managing Patients With HER2-Low Breast Cancer
19/02/2019 Duración: 14minManaging Patients With HER2-Low Breast Cancer
